Clinical Trial Update: Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease [Phase 2]

View source ↗

Summary

Open-label extension study results for pridopidine (ACR16) in symptomatic treatment of Huntington disease (Phase 2) completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Pridopidine (pridopidine)

Snippet

Sponsor: Prilenia | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-02-09